U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H33N5O4.C2H6O3S
Molecular Weight 649.7594
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NINTEDANIB ESYLATE

SMILES

CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4N=C3O)C(=O)OC)/c5ccccc5.CCS(=O)(=O)O

InChI

InChIKey=MMMVNAGRWOJNMW-FJBFXRHMSA-N
InChI=1S/C31H33N5O4.C2H6O3S/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38;1-2-6(3,4)5/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38);2H2,1H3,(H,3,4,5)/b29-28-;

HIDE SMILES / InChI

Molecular Formula C2H6O3S
Molecular Weight 110.1334
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C31H33N5O4
Molecular Weight 539.626
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=24782550; http://www.ncbi.nlm.nih.gov/pubmed/?term=21204634; http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2016/6-6-2016-boehringer-ingelheim-inventiva-collaborate-develop-potential-new-treatments-idiopathic-pulmonary-fibrosis.html

Nintedanib is a receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. It is the only kinase inhibitor drug approved to treat idiopathic pulmonary fibrosis. that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology.

CNS Activity

Curator's Comment:: Nintedanib (molecular weight 539 Da) does not cross the blood–brain barrier in normal rat brain (investigator’s brochure U03-1563), as is generally expected for molecules [300 Da].

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P17948|||B3FR89
Gene ID: 2321.0
Gene Symbol: FLT1
Target Organism: Homo sapiens (Human)
34.0 nM [IC50]
Target ID: P35968
Gene ID: 3791.0
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
21.0 nM [IC50]
Target ID: P35916
Gene ID: 2324.0
Gene Symbol: FLT4
Target Organism: Homo sapiens (Human)
13.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OFEV

Approved Use

Indicated for the treatment of idiopathic pulmonary fibrosis (IPF)

Launch Date

1.41333116E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.4 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
56.2 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NINTEDANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.2%
NINTEDANIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 61 years
n = 6
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Population Size: 6
Sources:
DLT: Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Sources:
250 mg 1 times / day steady, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: steady
Dose: 250 mg, 1 times / day
Sources:
unhealthy, 61 years
n = 4
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Population Size: 4
Sources:
DLT: Gamma-glutamyltransferase increased...
Dose limiting toxicities:
Gamma-glutamyltransferase increased (grade 3, 1 patient)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources:
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (5%)
Nausea (2%)
Decreased appetite (2%)
Sources:
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 15
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 15
Disc. AE: Weight decreased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Weight decreased (1.1%)
Alanine aminotransferase increased (0.6%)
Sources: Page: p. 15
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Disc. AE: Vomiting, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Abdominal pain (1%)
Asthenia (0.7%)
Hepatic enzyme increased (0.6%)
Aspartate aminotransferase increased (0.4%)
Blood bilirubin increased (0.4%)
Sources: Page: p. 87
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (10.9%)
Nausea (2.1%)
Decreased appetite (0.8%)
Weight decreased (0.6%)
Abdominal pain (0.8%)
Abdominal pain upper (0.8%)
Transaminases increased (0.4%)
Hepatic function abnormal (0.7%)
Sources: Page: p. 88
250 mg 2 times / day steady, oral
MTD
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
n = 11
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: adult
Population Size: 11
Sources:
DLT: Elevated liver enzymes...
Dose limiting toxicities:
Elevated liver enzymes (grade 3, 2 patients)
Sources:
600 mg 1 times / day multiple, oral
Overdose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: adult
Population Size: 1
Sources:
Other AEs: Nasopharyngitis...
600 mg 2 times / day multiple, oral
Overdose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adult
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: adult
Population Size: 2
Sources:
AEs

AEs

AESignificanceDosePopulation
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 61 years
n = 6
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Population Size: 6
Sources:
Gamma-glutamyltransferase increased grade 3, 1 patient
DLT
250 mg 1 times / day steady, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: steady
Dose: 250 mg, 1 times / day
Sources:
unhealthy, 61 years
n = 4
Health Status: unhealthy
Age Group: 61 years
Sex: M+F
Population Size: 4
Sources:
Decreased appetite 2%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources:
Nausea 2%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources:
Diarrhea 5%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources:
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources:
Alanine aminotransferase increased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 15
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 15
Weight decreased 1.1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 15
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 15
Aspartate aminotransferase increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Blood bilirubin increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Hepatic enzyme increased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Asthenia 0.7%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Abdominal pain 1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Vomiting 1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 87
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 87
Transaminases increased 0.4%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Weight decreased 0.6%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Hepatic function abnormal 0.7%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Abdominal pain upper 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Abdominal pain 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Decreased appetite 0.8%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Diarrhea 10.9%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Nausea 2.1%
Disc. AE
150 mg 2 times / day steady, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: steady
Dose: 150 mg, 2 times / day
Sources: Page: p. 88
unhealthy, 67 years (range: 42 - 89 years)
n = 723
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 42 - 89 years)
Sex: M+F
Population Size: 723
Sources: Page: p. 88
Elevated liver enzymes grade 3, 2 patients
DLT
250 mg 2 times / day steady, oral
MTD
Dose: 250 mg, 2 times / day
Route: oral
Route: steady
Dose: 250 mg, 2 times / day
Sources:
unhealthy, adult
n = 11
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: adult
Population Size: 11
Sources:
Nasopharyngitis
600 mg 1 times / day multiple, oral
Overdose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: adult
Population Size: 1
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 16 uM]
no [IC50 24.5 uM]
no [IC50 24.5 uM]
no [IC50 70.1 uM]
no [IC50 77.6 uM]
no [IC50 85.5 uM]
no [IC50 >200 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
yes [IC50 0.88 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: Coadministration with the P-gp and CYP3A4 inhibitor ketoconazole increased exposure of nintedanib by 1.61-fold based on AUC and 1.83-fold based on Cmax.
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
2008 Jun 15
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
2011 Apr
A new hope for idiopathic pulmonary fibrosis.
2014 May 29
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
2014 Sep
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
2015 Jul
Nintedanib in the treatment of idiopathic pulmonary fibrosis.
2015 Jun
Patents

Sample Use Guides

150 mg twice daily approximately 12 hours apart taken with food. Recommended dosage in patients with mild hepatic impairment: 100 mg twice daily approximately 12 hours apart taken with food. Consider temporary dose reduction to 100 mg, treatment interruption, or discontinuation for management of adverse reactions. Prior to treatment, conduct liver function tests and a pregnancy test
Route of Administration: Oral
10-80 nmol/L resulted in 50% inhibition (EC50) of cell proliferation in human umbilical vascular endothelial cell HUVEC, microvascular skin endothelial cells HMSEC, umbilical artery smooth muscle cells HUASMC
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:34:55 UTC 2021
Edited
by admin
on Fri Jun 25 20:34:55 UTC 2021
Record UNII
42F62RTZ4G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NINTEDANIB ESYLATE
USAN  
USAN  
Official Name English
METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO) (PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE ETHANESULFONATE
Systematic Name English
NINTEDANIB ETHANESULFONATE
Common Name English
NINTEDANIB ESYLATE [ORANGE BOOK]
Common Name English
NINTEDANIB ESYLATE [USAN]
Common Name English
NINTEDANIB ESILATE [WHO-DD]
Common Name English
NINTEDANIB ETHANESULFONATE [JAN]
Common Name English
OFEV
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1742
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
NCI_THESAURUS C155727
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
Code System Code Type Description
PUBCHEM
9809714
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
EPA CompTox
656247-18-6
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
JAPANESE REVIEW
OFEV
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY APPROVED JULY 2015
NCI_THESAURUS
C154570
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
CAS
656247-18-6
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
RXCUI
1592736
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY RxNorm
FDA UNII
42F62RTZ4G
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
EVMPD
SUB179667
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
DRUG BANK
DBSALT001111
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
MESH
C530716
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
ChEMBL
CHEMBL502835
Created by admin on Fri Jun 25 20:34:55 UTC 2021 , Edited by admin on Fri Jun 25 20:34:55 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY